Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer

被引：9

作者：

Kaburagi, Takayuki ^{[1
,2
]}

Satoh, Hiroaki ^{[3
]}

Hayashihara, Kenji ^{[4
]}

Endo, Takeshi ^{[5
]}

Hizawa, Nobuyuki ^{[6
]}

Kurishima, Koichi ^{[6
]}

Nishimura, Yoshihiro ^{[7
]}

Hashimoto, Toshio ^{[8
]}

Nakamura, Hiroyuki ^{[9
]}

Kishi, Koji ^{[9
]}

Inagaki, Masaharu ^{[10
,11
]}

Nawa, Takeshi ^{[12
]}

Ichimura, Hideo ^{[13
,14
]}

Ishikawa, Hiroichi ^{[13
,14
]}

Kagohashi, Katsunori

Fukuoka, Toshihiko ^{[15
]}

Shinohara, Yoko ^{[10
,11
]}

Kamiyama, Koichi ^{[16
]}

Sato, Yukio ^{[6
]}

Sakai, Mitsuaki ^{[6
]}

Matsumura, Takeshi ^{[17
]}

Uchiumi, Keiko ^{[1
,2
]}

Furukawa, Kinya ^{[9
]}

机构：

[1] Ibaraki Cent Hosp, Div Resp Med, Kasama, Ibaraki 3091793, Japan

[2] Reg Canc Ctr, Kasama, Ibaraki 3091793, Japan

[3] Univ Tsukuba, Div Resp Med, Mito Med Ctr, Mito, Ibaraki 3100015, Japan

[4] Ibaraki Higashi Hosp, Tokai, Ibaraki 3191113, Japan

[5] Mito Med Ctr Hosp, Ibaraki 3113193, Japan

[6] Univ Tsukuba Hosp, Tsukuba, Ibaraki 3058575, Japan

[7] Mito Chuo Hosp, Mito, Ibaraki 3111135, Japan

[8] Mito Saiseikai Hosp, Mito, Ibaraki 3114198, Japan

[9] Tokyo Med Univ, Kasumigaura Hosp, Ami, Ibaraki 3000395, Japan

[10] Tsuchiura Kyodo Gen Hosp, Tsuchiura, Ibaraki 3000053, Japan

[11] Reg Canc Ctr, Tsuchiura, Ibaraki 3000053, Japan

[12] Hitachi Gen Hosp, Hitachi, Ibaraki 3170077, Japan

[13] Tsukuba Med Ctr Hosp, Tsukuba, Ibaraki 3050005, Japan

[14] Reg Canc Ctr, Tsukuba, Ibaraki 3050005, Japan

[15] JA Toride Med Ctr, Toride, Ibaraki 3020022, Japan

[16] Tsukuba Kinen Hosp, Tsukuba, Ibaraki 3002622, Japan

[17] Ibaraki Seinan Gen Hosp, Sakai, Osaka 3060433, Japan

来源：

ONCOLOGY LETTERS | 2013年 / 5卷 / 02期

关键词：

erlotinib; non-small cell lung cancer; observational study; population-based; PREVIOUSLY TREATED PATIENTS; PHASE-II; GEFITINIB; CHEMOTHERAPY; MULTICENTER;

D O I：

10.3892/ol.2012.1048

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based observational study. The study involved 307 patients treated with erlotinib at 14 sites (17 departments) in Ibaraki (Japan) between December 2007 and December 2010. The tumor response and disease control rates were 11.1 and 46.3% in all patients, respectively. The median time to treatment failure and survival time were 1.6 months (95% confidence interval, 41-57 days) and 5.3 months (134-181 days) in all patients, respectively. Survival was significantly prolonged in EGFR mutation-positive patients compared with negative patients. EGFR mutation-negative patients who presented with a skin rash had significantly prolonged survival compared with those without a skin rash. The most common adverse event was skin disorder, followed by diarrhea. Although 45.6% of the patients in this study received erlotinib as a fourth-line or subsequent treatment, the results from this study were similar to those of clinical studies. We deduce that erlotinib is effective against NSCLC and is tolerated in clinical practice.

引用

页码：435 / 439

页数：5

共 12 条

[1]

[Anonymous], ANN ONCOL S8

[2]

[Anonymous], J CLIN ONCOL

[3] Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21 [J].

Bezjak, Andrea ;

Tu, Dongsheng ;

Seymour, Lesley ;

Clark, Gary ;

Trajkovic, Aleksandra ;

Zukin, Mauro ;

Ayoub, Joseph ;

Lago, Sergio ;

de Albuquerque Ribeiro, Ronaldo ;

Gerogianni, Alexandra ;

Cyjon, Arnold ;

Noble, Jonathan ;

Laberge, Francis ;

Chan, Raymond Tsz-Tong ;

Fenton, David ;

von Pawel, Joachim ;

Reck, Martin ;

Shepherd, Frances A. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3831-3837

[4]

Cappuzzo F, 2009, J CLIN ONCOL, V27

[5] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study [J].

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Miliauskas, Skaidrius ;

Grigorescu, Alexandru Calin ;

Hillenbach, Carina ;

Johannsdottir, Hrefna Kristin ;

Klughammer, Barbara ;

Esteban Gonzalez, Emilio .

LANCET ONCOLOGY, 2012, 13 (03) :300-308

[6] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[7] A population-based study of gefitinib in patients with non-small cell lung cancer [J].

Hayashibara, Kenji ;

Satoh, Hiroaki ;

Shinohara, Yoko ;

Inagaki, Masaharu ;

Kaburagi, Takayuki ;

Hashimoto, Toshio ;

Kurishima, Koichi ;

Ishikawa, Hiroichi ;

Ichimura, Hideo ;

Nawa, Takeshi ;

Funayama, Yasunori ;

Matsumura, Takeshi ;

Kagohashi, Katsunori ;

Endo, Takeshi ;

Furukawa, Kinya ;

Kishi, Koji ;

Sumi, Masaaki ;

Kamiyama, Koichi ;

Ishikawa, Shigemi .

MEDICAL ONCOLOGY, 2009, 26 (02) :222-227

[8] First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy [J].

Inoue, Akira ;

Kobayashi, Kunihiko ;

Usui, Kazuhiro ;

Maemondo, Makoto ;

Okinaga, Shoji ;

Mikami, Iwao ;

Ando, Masahiro ;

Yamazaki, Koichi ;

Saijo, Yasuo ;

Gemma, Akihiko ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Ikebuchi, Kenji ;

Nukiwa, Toshihiro ;

Morita, Satoshi ;

Hagiwara, Koichi .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1394-1400

[9] Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer A Phase II Study [J].

Kubota, Kaoru ;

Nishiwaki, Yutaka ;

Tamura, Tomohide ;

Nakagawa, Kazuhiko ;

Matsui, Kaoru ;

Watanabe, Koshiro ;

Hida, Toyoaki ;

Kawahara, Masaaki ;

Katakami, Nobuyuki ;

Takeda, Kohi ;

Yokoyama, Akira ;

Noda, Kazumasa ;

Fukuoka, Masahiro ;

Saijo, Nagahiro .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (12) :1439-1445

[10]

Massuti B, 2009, J CLIN ONCOL S, V27, p15s

← 1 2 →